West Pharmaceutical Services (WST) Income towards Parent Company (2009 - 2026)

West Pharmaceutical Services (WST) has reported Income towards Parent Company for 18 consecutive years, with $147.9 million the latest figure, recorded in Q2 2026.

• Quarterly Income towards Parent Company rose 16.64% year-over-year to $147.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $549.4 million (up 16.05% YoY) and the FY2025 annual result came in at $479.3 million, changed 0.27% from the prior year.
• Income towards Parent Company rose to $147.9 million in Q2 2026 per WST's latest filing, from $135.4 million in the prior quarter.
• Over the last five years, Income towards Parent Company for WST reached as high as $183.0 million in Q2 2022 and fell as low as $86.4 million in Q1 2025.
• A 5-year average of $132.3 million and a median of $132.9 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company tumbled 32.43% — and 2026, when it surged 56.71%.
• Year by year, Income towards Parent Company stood at $99.8 million in 2022, then surged by 33.97% to $133.7 million in 2023, then fell by 4.19% to $128.1 million in 2024, then climbed by 0.08% to $128.2 million in 2025, then increased by 15.37% to $147.9 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered $147.9 million, $135.4 million, and $128.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.